# Evaluation of a Lifestyle Intervention Adopted for Clinical Practice for Diabetes Prevention (ELEVATE-DP)

> **NIH NIH R18** · PALO ALTO MEDICAL FOUNDATION RES INST · 2021 · $601,379

## Abstract

PROJECT SUMMARY/ABSTRACT
 The Diabetes Prevention Program was a landmark randomized controlled trial that demonstrated the
efficacy of a structured and comprehensive lifestyle intervention in preventing type 2 diabetes (T2D). Due to its
large success, it was adapted for use in community settings by changing the intensive, individualized (one-on-
one) lifestyle intervention to a facilitated, group-based intervention (Group Lifestyle Balance™ [GLB]). While
the GLB program has been associated with modest improvements in weight management and a reduced
incidence of T2D in various community-based settings, reach has been limited. Healthcare system settings
hold great potential for implementing behavioral lifestyle interventions due to the clinical resources and access
to patients at risk for T2D. Natural experiments resulting from the spontaneous and organic implementation of
evidence-based interventions, such as GLB, into a real-world clinical practice provide a rare and exciting
opportunity to examine effectiveness in a truly pragmatic context.
 In the proposed study, Evaluation of a Lifestyle Intervention Adopted for Clinical Practice for Diabetes
Prevention (ELEVATE-DP), we seek to evaluate the GLB program after its integration within a large,
healthcare delivery system, Sutter Health (SH) of Northern California. SH is a mixed payer environment and
operates as a fee-for-service organization, much like the U.S. healthcare system as a whole. In 2010, two of
the five regional affiliates independently launched GLB programs. This allows for the unique opportunity to
rigorously evaluate the real-world effectiveness of the GLB program after integration within a healthcare
system, with high potential for the generalizability of findings to other similar health systems in the U.S. This
study will employ a rigorous mixed-methods evaluation approach, using a large, comprehensive electronic
health records (EHR) system, GLB program records, and prospectively collected primary data from past and
present GLB administrators, facilitators, and participants, as well as eligible non-participants. We will use the
EHR to retrospectively identify GLB participants (N=5,000) and a matched usual-care cohort (non-GLB
participants; N=10,000) between 2010 and 2016, and will add four years of additional data (2017-2020). The
Specific Aims are to: 1) Evaluate the clinical effectiveness of GLB relative to usual-care; 2) Evaluate the impact
of GLB on healthcare resource utilization and costs relative to usual-care, including a formal cost-effectiveness
analysis; and 3) Evaluate the implementation and fidelity of GLB within and across SH regional divisions and
clinics using a comparative mixed-methods process evaluation. This study will identify important barriers to
and facilitators of translating an efficacious diabetes prevention intervention into routine clinical
practice, outside of a research setting.

## Key facts

- **NIH application ID:** 10141221
- **Project number:** 5R18DK110739-05
- **Recipient organization:** PALO ALTO MEDICAL FOUNDATION RES INST
- **Principal Investigator:** Kristen M.J. Azar
- **Activity code:** R18 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $601,379
- **Award type:** 5
- **Project period:** 2017-04-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10141221

## Citation

> US National Institutes of Health, RePORTER application 10141221, Evaluation of a Lifestyle Intervention Adopted for Clinical Practice for Diabetes Prevention (ELEVATE-DP) (5R18DK110739-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10141221. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*